Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics (Elafibranor, Ocaliva, Selonsertib, Cenicriviroc, Emricasan, and Other Therapeutics), By Diagnostics (Imaging Techniques, Diagnostic Tests, and Biopsy), and By Geogr

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics (Elafibranor, Ocaliva, Selonsertib, Cenicriviroc, Emricasan, and Other Therapeutics), By Diagnostics (Imaging Techniques, Diagnostic Tests, and Biopsy), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Non-alcoholic steatohepatitis (NASH) is inflammation of the liver caused by excess fat cells in it (fatty liver disease). It is caused when that extra fat turns into inflammation (swelling in the liver) and fibrosis (scarring) of the liver. NASH is a hidden epidemic, and thus, there is an increase demand for safe and effective therapeutics and diagnostics.

Market Dynamics:

Rise in NASH-affected population, increase in diabetic and obese population, increase in demand for safe and effective NASH therapeutics and diagnostics, favorable initiatives by government and non-government organizations, and increasing awareness about NAFLD/NASH are major factors expected to propel the growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

For instance, in June 2022, Echosens and Novo Nordisk A/S announced a collaboration to advance the early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers, and other stakeholders. In June 2018, the first International NASH Day was launched by Global Liver Institute with the goal of raising awareness about NASH and the actions people can take to prevent the disease.

Key features of the study:

  • This report provides in-depth analysis of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market.
Detailed Segmentation:
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics:
  • Elafibranor
  • Ocaliva
  • Selonsertib
  • Cenicriviroc
  • Emricasan
  • Other Therapeutics
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics:
  • Imaging Techniques
  • Diagnostic Tests
  • Biopsy
  • Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
  • Company Profiles:
  • Novartis AG
  • Allergan Plc.
  • Viking Therapeutics
  • Merck & Co.
  • Zydus Cadila
  • Novo Nordisk A/S
  • GENFIT SA
  • Gilead Sciences Inc.
  • Galmed Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Intercept Pharmaceuticals Inc.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Therapeutics
Market Snapshot, By Diagnostics
Market Snapshot, By Geography
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Rise in NASH-affected population worldwide
Slow advancements in the therapeutic field
Rise in demand for safe/effective therapeutics and diagnostics
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Therapeutics, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Elafibranor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Ocaliva
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Selonsertib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Cenicriviroc
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Emricasan
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Other Therapeutics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
6. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Diagnostics, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
Imaging Techniques
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Diagnostic Tests
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Biopsy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
7. Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Geography, 2017-2030, (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2017 – 2030
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Middle East and Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
Rest of World
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2030,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2030,(US$ Mn)
8. Competitive Landscape
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Allergan Plc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Viking Therapeutics
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Zydus Cadila
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novo Nordisk A/S
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GENFIT SA
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Gilead Sciences Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Galmed Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Madrigal Pharmaceuticals
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Intercept Pharmaceuticals Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Views
9. Section
Research Methodology
About us
*Browse 24 market data tables and 28 figures on "Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market” - forecast to 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings